Position in LLY
as of Jun 30, 2026
· filed Jul 23, 2026
Position Value
$4,254,378
+$993,794 QoQ
Shares Held
3,547
+0.1% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.79%
of 13F equity value
Holder Rank
#1,840
of 4,605 holders
Holding Since
Sep 2023
12 quarters on record
Voting authority
Sole 89%
Shared 0%
None 11%
Common Shares in LLY Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Baker Ellis Asset Management LLC holds $17,156,761 across 7 Drug Manufacturers - General names. LLY ranks #1 (24.8% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LLY |
ELI LILLY & Co
This page
|
3,547 | $4,254,378 | |
| 2 | SNY |
Sanofi
|
81,342 | $3,470,049 | |
| 3 | JNJ |
Johnson & Johnson
|
13,294 | $3,376,277 | |
| 4 | NVS |
Novartis AG
|
14,950 | $2,342,964 | |
| 5 | MRK |
Merck & Co., Inc.
|
14,988 | $1,925,958 | |
| 6 | ABBV |
AbbVie Inc.
|
6,083 | $1,530,726 | |
| 7 | BMY |
Bristol Myers Squibb Co
|
4,450 | $256,409 |
All Filings in LLY
Export CSV
12 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $4,254,378 | 3,547 | Shares | Sole | 2026-07-23 | |
| 2026-03-31 | $3,260,584 | 3,545 | Shares | Sole | 2026-04-17 | |
| 2025-12-31 | $3,800,068 | 3,536 | Shares | Sole | 2026-01-21 | |
| 2025-09-30 | $2,640,743 | 3,461 | Shares | Sole | 2025-10-23 | |
| 2025-06-30 | $311,812 | 400 | Shares | Sole | 2025-07-08 | |
| 2025-03-31 | $330,364 | 400 | Shares | Sole | 2025-04-15 | |
| 2024-12-31 | $331,960 | 430 | Shares | Sole | 2025-01-17 | |
| 2024-09-30 | $354,376 | 400 | Shares | Sole | 2024-10-15 | |
| 2024-06-30 | $362,152 | 400 | Shares | Sole | 2024-07-09 | |
| 2024-03-31 | $338,412 | 435 | Shares | Sole | 2024-04-17 | |
| 2023-12-31 | $233,168 | 400 | Shares | Sole | 2024-01-23 | |
| 2023-09-30 | $214,852 | 400 | Shares | Sole | 2023-10-24 | |
| No filing history on record for this holder in this stock. | ||||||